Literature DB >> 34050922

Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship.

Agnieszka Karkucinska-Wieckowska1, Ines C M Simoes2, Piotr Kalinowski3, Magdalena Lebiedzinska-Arciszewska2, Krzysztof Zieniewicz3, Piotr Milkiewicz4,5, Magdalena Górska-Ponikowska6, Paolo Pinton7, Afshan N Malik8, Marcin Krawczyk9,10, Paulo J Oliveira11, Mariusz R Wieckowski2.   

Abstract

According to the 'multiple-hit' hypothesis, several factors can act simultaneously in nonalcoholic fatty liver disease (NAFLD) progression. Increased nitro-oxidative (nitroso-oxidative) stress may be considered one of the main contributors involved in the development and risk of NAFLD progression to nonalcoholic steatohepatitis (NASH) characterized by inflammation and fibrosis. Moreover, it has been repeatedly postulated that mitochondrial abnormalities are closely related to the development and progression of liver steatosis and NAFLD pathogenesis. However, it is difficult to determine with certainty whether mitochondrial dysfunction or oxidative stress are primary events or a simple consequence of NAFLD development. On the one hand, increasing lipid accumulation in hepatocytes could cause a wide range of effects from mild to severe mitochondrial damage with a negative impact on cell fate. This can start the cascade of events, including an increase of cellular reactive nitrogen species (RNS) and reactive oxygen species (ROS) production that promotes disease progression from simple steatosis to more severe NAFLD stages. On the other hand, progressing mitochondrial bioenergetic catastrophe and oxidative stress manifestation could be considered accompanying events in the vast spectrum of abnormalities observed during the transition from NAFL to NASH and cirrhosis. This review updates our current understanding of NAFLD pathogenesis and clarifies whether mitochondrial dysfunction and ROS/RNS are culprits or bystanders of NAFLD progression.
© 2021 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  ROS; mitochondria; mitochondrial dysfunction; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; oxidative stress

Mesh:

Year:  2021        PMID: 34050922     DOI: 10.1111/eci.13622

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

1.  Developmental Programming: Prenatal Testosterone Excess on Liver and Muscle Coding and Noncoding RNA in Female Sheep.

Authors:  Nadia Saadat; Muraly Puttabyatappa; Venkateswaran R Elangovan; John Dou; Joseph N Ciarelli; Robert C Thompson; Kelly M Bakulski; Vasantha Padmanabhan
Journal:  Endocrinology       Date:  2022-01-01       Impact factor: 4.736

Review 2.  NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook.

Authors:  Alberto Nascè; Karim Gariani; François R Jornayvaz; Ildiko Szanto
Journal:  Antioxidants (Basel)       Date:  2022-06-09

3.  Pre-germinated brown rice alleviates non-alcoholic fatty liver disease induced by high fructose and high fat intake in rat.

Authors:  Pei-Wen Cheng; Hsin-Li Liang; Hui-Li Lin; Chi-Long Hao; Yu-Hsiu Tseng; Yi-Chen Tu; Bor-Chun Yeh; Kuo-Ping Shen
Journal:  J Clin Biochem Nutr       Date:  2022-03-24       Impact factor: 3.179

Review 4.  Impact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease.

Authors:  José Ignacio Martínez-Montoro; Isabel Cornejo-Pareja; Ana María Gómez-Pérez; Francisco J Tinahones
Journal:  Nutrients       Date:  2021-11-15       Impact factor: 5.717

5.  HtrA2/Omi mitigates NAFLD in high-fat-fed mice by ameliorating mitochondrial dysfunction and restoring autophagic flux.

Authors:  Wei Zhou; Xueting Deng; Xiaolei Zhu; Qinhui Yan; Nan Zhou; Susu Du; Xiaonan Li
Journal:  Cell Death Discov       Date:  2022-04-21

6.  Hepatic Mitochondrial Dysfunction and Risk of Liver Disease in an Ovine Model of "PCOS Males".

Authors:  Katarzyna J Siemienowicz; Panagiotis Filis; Jennifer Thomas; Paul A Fowler; W Colin Duncan; Mick T Rae
Journal:  Biomedicines       Date:  2022-05-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.